Landmark Trial to Determine Value of Invasive Heart Monitoring Devices
Table of Contents
A new, patient-centered clinical trial is underway to definitively determine whether invasive devices used to monitor cardiac function during and after open-heart surgery truly benefit patients, or if they pose unnecessary risks. The study, involving over 20,000 Australians annually, marks a significant step toward optimizing post-operative care and reducing the burden on healthcare systems.
The PUMA trial, led by the Monash Victorian Heart Institute, will directly compare the widely used pulmonary artery catheter (PAC) with the central venous catheter (CVC) – a less invasive alternative. Researchers anticipate that adopting the CVC could lead to fewer unnecessary treatments, shorter stays in intensive care units, reduced healthcare expenditures, and a substantial decrease in the environmental impact of intensive care by 2030.
“These invasive devices have been broadly de-adopted in other high-risk patient groups after large clinical trials due to sepsis, acute respiratory distress syndrome, and use in non-cardiac surgery failing to show a benefit to patients,” explained a lead investigator from the Victorian Heart Institute. “PUMA will resolve decades of international controversy around the role of pulmonary artery catheters in contemporary practice, paving the way for high-value care that could reduce major complications and get patients home to their families sooner.”
Patient Voices Drive Research Priorities
What sets the PUMA trial apart is its commitment to co-design, actively incorporating the perspectives of patients and their families throughout the research process. The insights of Paige Druce, a two-time cardiac surgery survivor serving as a lived-experience investigator, were instrumental in shaping the study’s focus and priorities from the initial pilot phase.
“It is important to feel confident that every procedure is truly necessary,” Druce stated. “Co-designing clinical trials with people who have lived experience is important because it helps to make sure the research focuses on things that matter to the people it’s meant to help.” Druce further emphasized that this collaborative approach ensures the research is conducted with fairness and respect for all participants.
Balancing Risk and Reward in Cardiac Monitoring
Associate Professor Lachlan Miles, a PUMA co-investigator and Head of Research in the Department of Anaesthesia at Austin Health, highlighted the complexities of cardiac monitoring. “Pulmonary artery catheters provide important information about heart function,” Miles said. “Unfortunately, they are not without risk, and could even trigger unnecessary treatments, increase complications and prolong hospital admissions.” The trial aims to provide definitive data to guide clinical practice and optimize patient outcomes.
The PUMA trial has received endorsement from the Australia and New Zealand College of Anaesthetists Clinical Trials Network, signaling its importance and rigor. Recruitment for the 2,000-patient study is scheduled to begin in Australia and internationally later this year.
.
The PUMA trial represents a pivotal moment in cardiac care, promising to deliver evidence-based insights that will ultimately improve the lives of countless patients undergoing open-heart surgery.
